Abstract: Systems and methods are described for parallel macromolecular delivery and biochemical/electrochemical interface to whole cells employing carbon nanostructures including nanofibers and nanotubes. A method includes providing a first material on at least a first portion of a first surface of a first tip of a first elongated carbon nanostructure; providing a second material on at least a second portion of a second surface of a second tip of a second elongated carbon nanostructure, the second elongated carbon nanostructure coupled to, and substantially parallel to, the first elongated carbon nanostructure; and penetrating a boundary of a biological sample with at least one member selected from the group consisting of the first tip and the second tip.
Type:
Grant
Filed:
April 7, 2003
Date of Patent:
March 31, 2015
Assignee:
UT-Battelle, LLC
Inventors:
Timothy E. McKnight, Anatoli V. Melechko, Guy D. Griffin, Michael A. Guillorn, Vladimir L. Merkulov, Michael L. Simpson
Abstract: The present invention provides systems and methods for improving the efficiency of a transient gene delivery system to differentiating embryonic stem (ES) cells by serum starving the targeted cells for one to three days prior to transfection. Such a serum starvation surprisingly resulted in increased expression of a constitutively-controlled plasmid from 50.4% to 83.2% of the population and increased expression of a promoter/enhancer controlled plasmid from ˜1.4% to ˜3.7% of the population.
Type:
Grant
Filed:
September 22, 2009
Date of Patent:
March 31, 2015
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Martin L. Yarmush, Eric J. Wallenstein, Rene S. Schloss
Abstract: The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
March 31, 2015
Assignees:
The Brigham and Women's Hospital, Inc., The General Hospital Corporation
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Type:
Grant
Filed:
May 12, 2014
Date of Patent:
March 31, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
Abstract: Provided are a method of improving iPS cell establishment efficiency, comprising the step of transferring Lin28B or a nucleic acid that encodes Lin28B to a somatic cell, particularly to a somatic cell on which Lin28 is ineffective or less effective than Lin28B in improving iPS cell establishment efficiency, and a method of producing an iPS cell, comprising the step of transferring Lin28B or a nucleic acid that encodes Lin28B and a nuclear reprogramming substance to a somatic cell. Also provided are an iPS cell comprising a nucleic acid that encodes Lin28B, that can be obtained by the method of producing an iPS cell, and a method of somatic cell production by forcing the iPS cell to differentiate into a somatic cell.
Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
March 31, 2015
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Abstract: A composition of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle, the extract being used for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.
Type:
Grant
Filed:
May 5, 2014
Date of Patent:
March 31, 2015
Assignee:
Centre National de la Recherche Scientifique
Abstract: The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of Homeobox-B8 protein and FMS-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, Homeobox-A7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types.
Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
Abstract: This invention relates to improved methods of genetically modifying animal cells by decreasing the distance between cells and genetic modification agents in order to increase the efficiency of genetic modification and/or reduce use of gene modification agents.
Abstract: This disclosure provides for compositions and methods for the use of designed nucleic acid-targeting nucleic acids, Argonautes, and complexes thereof.
Type:
Application
Filed:
April 10, 2014
Publication date:
March 26, 2015
Applicant:
Caribou Biosciences, Inc.
Inventors:
John VAN DER OOST, Daniël Christianus SWARTS, Andrew Paul MAY, Rachel E. HAURWITZ
Abstract: The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically inactive variants comprising deletions or other mutations are provided.
Abstract: The present invention is related to a nucleic acid construct comprising an expression unit for the expression of E1B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1B, and a 3?UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1B, wherein the 3?UTR comprises 30 or less than 30 Exonic Enhancer Elements (ESEs), preferably 20 or less than 20 Exonic Enhancer Elements (ESEs), and wherein the 3? UTR is a non-viral 3? UTR.
Abstract: An automated cell injection system and method are described, which can perform automatic, reliable, and high-throughput cell injection of foreign genetic materials, proteins, and other compounds. The system and method overcome the problems inherent in traditional manual injection that is characterized by poor reproducibility, human fatigue, and low throughput. The present invention is particularly suited for zebrafish embryo injection but can be readily extended to other biological injection applications such as mouse embryo, drosophila embryo, and C. elegans injections, capable of facilitating high-throughput genetic research at both academic and industry levels. A novel vacuum based cell-holding device is also provided.
Abstract: The present invention relates to methods and compositions for enhancing folding and stability of biological molecules. In particular, the present invention relates to methods and compositions for identifying biological molecules with enhanced stability. The present invention further relates to host cells that confer enhanced stability to biological molecules expressed therein.
Type:
Grant
Filed:
August 27, 2008
Date of Patent:
March 24, 2015
Assignee:
The Regents of the University of Michigan
Inventors:
James Bardwell, Linda Foit, Ajamaluddin Malik, Tobias Baumann, Maximilian Kern
Abstract: The invention provides compositions and methods for treating or preventing hearing loss in a subject. The method comprises administering to the subject in need thereof, at least Myc or an agent that increases the expression of Myc in an inner ear organ, or associated neural structures, of the subject so as to treat or prevent the hearing loss.
Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
Type:
Application
Filed:
September 16, 2014
Publication date:
March 19, 2015
Inventors:
Marie-Cecile van de Lavoir, Robert Etches
Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
Abstract: The present invention provides for a genetically modified eukaryotic host cell comprising (a) a gene encoding a first nucleotide sugar transporter (NST) operably linked to a promoter, wherein the gene and/or the promoter is heterologous to the cell, and/or (b) a native gene encoding a second NTS is disrupted and/or a promoter of the native gene is disrupted. Such modified cells can be altered in the production of polysaccharide and/or glycopeptides. The present invention also provides for methods of making or using such modified cells.
Type:
Application
Filed:
June 16, 2014
Publication date:
March 19, 2015
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Henrik Vibe Scheller, Carsten Rautengarten, Berit Ebert, Joshua L. Heazlewood
Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring ionic or voltage responses to contact with bioactive agents. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities.
Abstract: Isolated pluralities of T cells which recognize at least one epitope of a mucosally restricted antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of a mucosally restricted antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of a mucosally restricted antigen and T cells comprising such nucleic acid molecules.
Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
Abstract: This invention relates to a method for stably expressing a transgene integrated into the genome of an animal cell or of an animal over a long period. Specifically, this invention provides: an approximately 2.5 kb XhoI-BamHI fragment (or XB fragment) derived from the Evx2-Hoxd13 intergenic region of the animal genome, or a homologue thereof; a DNA containing a foreign DNA wherein the DNA has been inserted between the two essentially identical XB fragments or homologues thereof; a vector, animal cell, or nonhuman mammalian animal containing said DNA; and use of the vector, animal cell, or nonhuman mammalian animal for production of a substance or therapy.
Abstract: Provided herein are methods for stable integration and/or expression of one or more recombinant polynucleotides in a host cell. The recombinant polynucleotides are typically integrated into the host genome at some native chromosomal integration sites. The integration can be mediated by homologous recombination or by using a hybrid recombinase targeting the specific chromosomal locations. The native chromosomal integration sites in the host cells, which support stable integration and strong transcription activities of foreign genes, are present within or adjacent to specific genes in the CHO genome, the ankyrin 2 gene (Ank2), cleavage and polydenylation specific factor 4 gene (Cpsf4), C-Mos gene, and Nephrocystin-1/Mal gene. Also provided are methods and nucleic acid molecules for inserting site-specific recombination sequences (chromosomal landing pads) into these specific chromosomal locations, engineered host cells containing chromosomal landing pads, methods and compositions (e.g., kits) therefore.
Type:
Grant
Filed:
April 5, 2012
Date of Patent:
March 17, 2015
Assignee:
The Scripps Research Institute
Inventors:
Vincent P. Mauro, Wei Zhou, Bruce Cunningham, Gerald M. Edelman
Abstract: Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
Type:
Application
Filed:
August 19, 2014
Publication date:
March 12, 2015
Inventors:
Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc?RI, Fc?RIIA, and Fc?RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
Type:
Grant
Filed:
August 23, 2013
Date of Patent:
March 10, 2015
Assignee:
Janssen Biotech, Inc.
Inventors:
Michael Naso, T. Shantha Raju, Bernard Scallon
Abstract: Provided herein are biodegradable copolymers and nanoplex delivery systems comprising the same and a cargo molecule, such as a nucleic acid, a polynucleotide or other biomolecule. The biodegradable copolymers may comprise a reducible polymer linearly modified with lysine, such as a linear lysine-modified N,N?-cystamine bisacrylamide. The biodegradable copolymers also may be conjugated to a sequestering moiety, such as dietheylamine. The biodegradable copolymers also may comprise one or both of a targeting moiety and one or more moieties to facilitate endosomal escape. Also provided are methods for treating a pathophysiological condition and for increasing biocompatibility of a polymeric delivery system upon delivery to a subject using the biodegradable copolymers and nanoplexes.
Abstract: Provided is a method for effectively expressing mouse olfactory receptor Olfr15 on the cell membrane. The method includes steps of: bringing a cell into contact with a culture medium containing chlorpromazine; separating the culture medium from the cell so as to remove the culture medium; and incubating the cell using a culture medium which does not contain chlorpromazine to express the mouse olfactory receptor Olfr15 on the cell membrane.
Abstract: The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
Type:
Grant
Filed:
September 10, 2009
Date of Patent:
March 10, 2015
Assignee:
Institut CataláD'oncologia
Inventors:
Manel Maria Cascallo Piqueras, Alena Gros, Ramon Alemany Bonastre
Abstract: Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three ?-sheets and two ?-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.
Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
Type:
Application
Filed:
November 14, 2014
Publication date:
March 5, 2015
Inventors:
DANIEL M. GORMAN, TROY D. RANDALL, ALBERT ZLOTNIK
Abstract: The present invention provides a method for inhibiting cell growth, a nucleic acid molecule useful as an anticancer agent, and a method for screening novel anticancer agents. In the present invention, inhibitory effects on expression of NEK10 variant gene or inhibitory effects on activity of NEK10 variant protein are obtained in cells by transfecting cells with a nucleic acid molecule having an RNA interference effect on NEK10 variant gene. The present invention also provides a method for screening anticancer agents by using this inhibitory effect as an indicator.
Abstract: Provided herein are compositions comprising a micelle having a hydrophobic superparmagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising a polynucleotide. Also provided are methods of using the compositions for transfection and/or transformation of a cell with the polynucleotide. Further provided are methods of detecting transfection of a cell with the polynucleotide.
Type:
Application
Filed:
September 28, 2012
Publication date:
March 5, 2015
Applicant:
University of South Florida (A Florida Non-Profit Corporation)
Abstract: The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1.
Type:
Grant
Filed:
November 7, 2011
Date of Patent:
March 3, 2015
Assignee:
The Regents of the University of California
Inventors:
Brian P. Head, Piyush M. Patel, Hemal Patel, David M. Roth
Abstract: The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of stimulating an immune response to a tumor by administering a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a gp96 polypeptide.
Type:
Grant
Filed:
March 19, 2009
Date of Patent:
March 3, 2015
Assignee:
University of Miami
Inventors:
Eckhard R. Podack, Joseph R. Rosenblatt
Abstract: In an aspect, the invention relates to compositions and methods for enhancing cardiac tissue and/or cell regeneration. In an aspect, the invention relates to compositions and methods for attenuating adverse cardiac tissue and/or cell remodeling. In an aspect, the invention relates to compositions and methods for inhibiting apoptosis. In an aspect, the invention relates to compositions and methods for identifying a myocardial injury. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Abstract: The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.
Abstract: Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.
Type:
Application
Filed:
August 19, 2013
Publication date:
February 26, 2015
Applicant:
University of Central Florida Research Foundation, Inc.
Abstract: The present invention relates to branched polymer comprising a support moiety and at least three block co-polymer chains covalently coupled to and extending from the moiety, wherein: (i) each of the at least three block co-polymer chains comprise (a) a cationic polymer block that is covalently coupled to a hydrophilic polymer block, or (b) a cationic polymer block that is covalently coupled to a hydrophobic polymer block, said hydrophobic polymer block being covalently coupled to a hydrophilic polymer block; and (ii) at least one of said covalent couplings associated with each of said block co-polymer chains is biodegradable.
Type:
Application
Filed:
February 1, 2013
Publication date:
February 26, 2015
Inventors:
Pathiraja Arachchillage Gunatillake, Tracey Michelle Hinton, San Thang, Mark Leslie Tizard
Abstract: The polymeric carrier for delivering nucleic acid material to a cell is provided herein. The polymeric carrier can include a dendrimer group having 2 to 8 termini, each of the termini having an arginine-grafted bioreducible polymer attached thereto. In one embodiment, only a portion of the termini can have an arginine-grafted bioreducible polymer attached thereto.
Type:
Application
Filed:
January 18, 2013
Publication date:
February 26, 2015
Inventors:
Sung Wan Kim, Hye Yeong Nam, Kihoon Nam, David A. Bull
Abstract: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention further provides a pharmaceutical composition comprising Oct4 cDNA and SirT1 cDNA, or a polynucleotide comprising Oct4 cDNA and SirT1 cDNA.
Abstract: A variety of methods, devices and compositions are implemented for light-activated molecules. One such method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor (alpha1, Beta2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
February 24, 2015
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a DHFR expression cassette. Those cell lines have improved growth characteristics in comparison to DHFR-deficient or DHFR-reduced cell lines such as CHO DG44 and CHO DUKX-B11. The invention especially concerns two cell lines, a representative of each cell line is deposited with the DSMZ under the number DSM ACC2909 (CHOpper® Discovery) and DSM ACC2910 (CHOpper® Standard). The invention further concerns a method of producing proteins using the cells generated by the described method.
Type:
Grant
Filed:
July 22, 2009
Date of Patent:
February 24, 2015
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Hitto Kaufmann, Lore Florin, Eric Becker, Joey M. Studts
Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
February 24, 2015
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Guangping Gao, James M. Wilson, Mauricio R. Alvira
Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
February 24, 2015
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Guangping Gao, James M. Wilson, Mauricio R. Alvira
Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.
Abstract: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.